Meprednisone

Meprednisone Reactions 1680, p218 - 2 Dec 2017 Osteoporosis and multiple vertebral fractures: case report A 71-year-old woman developed osteoporosis and multiple vertebral fractures during treatment with meprednisone [route not stated; not all times to reactions onsets and outcomes not stated]. The woman, who was diagnosed with lupus nephropathy was started on meprednisone 40 mg/day. During the first year of meprednisone therapy, she experienced multiple vertebral fractures. Considering the severity of the woman’s osteoporosis and a glomerular filtration rate of 58 mL/min, she received a single dose of zoledronic acid. However, she continued to experience vertebral fractures in spite of corrective treatment. She was then referred for a bone and mineral metabolism evaluation. She was receiving meprednisone 4 mg/day and omeprazole at the time of the bone and mineral metabolism assessment. Simple radiographs of the spine demonstrated multiple vertebral fractures. A bone mineral density assessment was performed using dual-energy X-ray absorptiometry. The findings of this assessment were total right femur (TRF): 0.710 g/cm , T-score: –2.4; total left femur 2 2 (TLF): 0.706 g/cm , T-score: –2.5 and LS (L2–L4): 0.772 g/cm , T-score: –3.6. The laboratory parameters of mineral metabolism were within the reference ranges. Subsequently, she was started on subcutaneous teriparatide [Forteo] 20 µg/day for her meprednisone-induced osteoporosis, and her meprednisone dose was 2 mg/day at that time. Three months following the initiation of teriparatide treatment, laboratory investigations demonstrated an elevated uric acid level of 7.6 mg/dL. Thereafter, the frequency of teriparatide administration was reduced to three times weekly. Four months later, her uric acid level normalised. Seven months following the initiation of teriparatide therapy, meprednisone was discontinued. Nine months after teriparatide was started, a bone mineral density reassessment was performed, which revealed a 5% reduction in LS with stable TRF and TLF values. She reported injecting teriparatide at night in the abdominal region. She was then advised to administer the teriparatide injection in the morning following breakfast. After the change in the administration time and with three weekly doses of teriparatide, her LS and TLF bone mineral density increased by 9% and 3%, respectively after 16 months and by 18% and 5%, respectively after 22 months of teriparatide therapy. Concurrently, her TRF bone mineral density was stable. Thereafter, she did not experience any new fractures and tolerated the treatment well. The only adverse event that was related to teriparatide therapy was hyperuricaemia, which resolved following dose reduction. Author comment: "This work describes the case of a 71-yr-old woman diagnosed with lupus nephropathy treated with 40 mg/d of meprednisone, and who suffered multiple vertebral fractures." "Glucocorticoid (GC) treatment is the most frequent cause of secondary osteoporosis." Mastaglia SR. Effect of Time of Administration of Teriparatide on Bone Mineral Density in Glucocorticoid-Induced Osteoporosis. Journal of Clinical Densitometry 20: 513-515, No. 4, Oct-Dec 2017. Available from: URL: http://doi.org/10.1016/ j.jocd.2017.05.005 - Argentina 803284709 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Meprednisone

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/meprednisone-bffudhK8k3
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39149-5
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p218 - 2 Dec 2017 Osteoporosis and multiple vertebral fractures: case report A 71-year-old woman developed osteoporosis and multiple vertebral fractures during treatment with meprednisone [route not stated; not all times to reactions onsets and outcomes not stated]. The woman, who was diagnosed with lupus nephropathy was started on meprednisone 40 mg/day. During the first year of meprednisone therapy, she experienced multiple vertebral fractures. Considering the severity of the woman’s osteoporosis and a glomerular filtration rate of 58 mL/min, she received a single dose of zoledronic acid. However, she continued to experience vertebral fractures in spite of corrective treatment. She was then referred for a bone and mineral metabolism evaluation. She was receiving meprednisone 4 mg/day and omeprazole at the time of the bone and mineral metabolism assessment. Simple radiographs of the spine demonstrated multiple vertebral fractures. A bone mineral density assessment was performed using dual-energy X-ray absorptiometry. The findings of this assessment were total right femur (TRF): 0.710 g/cm , T-score: –2.4; total left femur 2 2 (TLF): 0.706 g/cm , T-score: –2.5 and LS (L2–L4): 0.772 g/cm , T-score: –3.6. The laboratory parameters of mineral metabolism were within the reference ranges. Subsequently, she was started on subcutaneous teriparatide [Forteo] 20 µg/day for her meprednisone-induced osteoporosis, and her meprednisone dose was 2 mg/day at that time. Three months following the initiation of teriparatide treatment, laboratory investigations demonstrated an elevated uric acid level of 7.6 mg/dL. Thereafter, the frequency of teriparatide administration was reduced to three times weekly. Four months later, her uric acid level normalised. Seven months following the initiation of teriparatide therapy, meprednisone was discontinued. Nine months after teriparatide was started, a bone mineral density reassessment was performed, which revealed a 5% reduction in LS with stable TRF and TLF values. She reported injecting teriparatide at night in the abdominal region. She was then advised to administer the teriparatide injection in the morning following breakfast. After the change in the administration time and with three weekly doses of teriparatide, her LS and TLF bone mineral density increased by 9% and 3%, respectively after 16 months and by 18% and 5%, respectively after 22 months of teriparatide therapy. Concurrently, her TRF bone mineral density was stable. Thereafter, she did not experience any new fractures and tolerated the treatment well. The only adverse event that was related to teriparatide therapy was hyperuricaemia, which resolved following dose reduction. Author comment: "This work describes the case of a 71-yr-old woman diagnosed with lupus nephropathy treated with 40 mg/d of meprednisone, and who suffered multiple vertebral fractures." "Glucocorticoid (GC) treatment is the most frequent cause of secondary osteoporosis." Mastaglia SR. Effect of Time of Administration of Teriparatide on Bone Mineral Density in Glucocorticoid-Induced Osteoporosis. Journal of Clinical Densitometry 20: 513-515, No. 4, Oct-Dec 2017. Available from: URL: http://doi.org/10.1016/ j.jocd.2017.05.005 - Argentina 803284709 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off